Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788744 | 1.00 | LMNA (0.32) | LMNAGAAMAPT | |
| SCHEMBL3710405 | 1.00 | LMNA (0.32) | LMNAGAAMAPT | |
| Hydrochloric Acid SCHEMBL8761720 | 0.98 | LMNA (0.32) | LMNAGAAMAPT | |
| Hydrochloric Acid SCHEMBL8761707 | 0.98 | LMNA (0.32) | LMNAGAAMAPT | |
| SCHEMBL9815219 | 0.87 | LMNA (0.31) | LMNAGAAMAPT | |
| SCHEMBL8569731 | 0.87 | LMNA (0.31) | LMNAGAAMAPT | |
| SCHEMBL8574244 | 0.86 | LMNA (0.38) | LMNAGAAMAPT | |
| SCHEMBL2454341 | 0.86 | LMNA (0.38) | LMNAGAAMAPT | |
| SCHEMBL2454344 | 0.86 | LMNA (0.38) | LMNAGAAMAPT | |
| SCHEMBL9199085 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2021-06-08 | — | — | US | disclosed |
| EP-3441071-A1 | DERIVATIZED CEPHALOSPORINS | Gladius Pharmaceuticals Corporation (CA) | 2019-02-13 | — | — | EP | disclosed |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-11-08 | — | — | US | disclosed |
| EP-2968352-B1 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | GLADIUS PHARMACEUTICALS CORP (CA) | 2018-09-26 | — | — | EP | disclosed |
| US-9975905-B2 | Derivatized 3-styryl-cephalosporins | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2018-05-22 | — | — | US | disclosed |
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SOPHARMIA, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2968352-A2 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | Gladius Pharmaceuticals Corporation (CA) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165126-A2 | DERIVATIZED 3-STYRYL-CEPHALOSPORINS | SOPHARMIA, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2010089729-A1 | PROCESSES FOR THE PREPARATION OF CEFOZOPRAN, ITS SALTS AND POLYMORPHIC FORMS THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| US-5998611-A | Process for producing cephem compounds in an aqueous medium | EISAI CHEMICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0303223-B1 | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5104866-A | WATER-SOLUBLE ANTIBIOTIC COMPOSITION AND WATER-SOLUBLE SALTS OF CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0253329-B1 | CEPHALOSPORIN INJECTION COMPOSITION | Eisai Co., Ltd. (JP) | 1991-05-29 | — | — | EP | disclosed |
| US-5010188-A | Cephem derivatives | EISAI CO., LTD. (JP) | 1991-04-23 | — | — | US | disclosed |
| US-5008260-A | Bactericides | EISAI CO., LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| EP-0188255-B1 | CEPHEM DERIVATIVES | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0303223-A2 | Water-soluble antibiotic composition and water-soluble salts of new cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
| US-4748171-A | Cephem compounds having at the 3-position a (1,4-methylene-1-piperidinio)methyl group or a (1-quinuclidinio)methyl group | EISAI CO., LTD. (JP) | 1988-05-31 | — | — | US | disclosed |
| EP-0253329-A2 | Cephalosporin injection composition | Eisai Co., Ltd. (JP) | 1988-01-20 | — | — | EP | disclosed |
| EP-0188255-A2 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031906-A1 | Derivatized 3-Styryl-Cephalosporins | SI, ENGASE, CMBL | LMNA 373/4885GAA 24/4885MAPT 3344/4885 |
| US-20180319817-A1 | Derivatized 3-Styryl-Cephalosporins | PEPD, SI, NAALAD2 | LMNA 532/4885GAA 56/4885MAPT 4037/4885 |
| US-11028103-B2 | Derivatized 3-styryl-cephalosporins | PEPD, SI, NAALAD2 | LMNA 532/4885GAA 56/4885MAPT 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.